Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

Nyxoah’s hypoglossal nerve stimulation system, Genio, met the co-primary endpoints at 12 months in the pivotal DREAM trial in adults with obstructive sleep apnoea (OSA). OSA is a sleep disorder where ...

New York-based home sleep diagnostics company Wesper has released findings from a case study on hypoglossal nerve stimulation ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

Christopher Hartnick, MD, director of the Division of Pediatric Otolaryngology at Mass Eye and Ear, displays the hypoglossal nerve stimulation implant in his office in Boston. Disclaimer ...

Inspire is a hypoglossal nerve stimulator (HNS) to treat obstructive sleep apnea. It is an implantable device that stimulates nerves controlling the tongue. The device causes the tongue to move ...

Deep brain stimulation can significantly reduce depressive symptoms in some individuals. Knowing what to expect before and after the procedure may help you determine if it’s right for you.

Saint Louis University’s Geriatric Education Center (GEC) offers cognitive stimulation therapy (CST), a support group for people experiencing memory challenges. Cognitive stimulation therapy (CST) is ...

Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that delivers magnetic pulses to the brain to change neural activity. It is used to treat mental health disorders, particularly ...

LivaNova (LIVN) “announced that it met the primary endpoints for its OSPREY randomized controlled trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with ...